Akebia Therapeutics opened lower at $0.57, compared with its previous close of $0.57. In the last trading session, the stock traded between $0.50 and $0.57. It showed a downward intraday trend.
Return calculator
Time Period
An investment of $100 made 5 years ago in Akebia Therapeutics is now worth
$ 16.88
Resulting in a loss of
$ 83.12 (83.12%)
Invest with $1
Note: Past profits do not guarantee future returns.
Analyst Overview
Rating from 4 Analysts
Buy
100%
Hold
0%
Sell
0%
Markets Today
Today's Change
$-0.08 (-13.20%)
Day High
$0.57
Day Low
$0.50
Day Open
$0.57
Prev Close
$0.57
Volume
37,06,558
1W Return
-27.93%
1M Return
-37.04%
3M Return
-42.49%
6M Return
-56.70%
1Y Return
-72.49%
Fundamentals
Market Cap ($ Mn)
138
PE Ratio
-
PB Ratio
9.56
PEG Ratio
-
ROE
-33.91%
ROCE
9.93%
EPS (TTM)
$-0.05
Investment Returns
1 Week
-27.93%
1 Month
-37.04%
3 Months
-42.49%
6 Months
-56.70%
9 Months
-67.87%
Financials
Quarterly
All values in $ Mn
57.3
Mar 25
62.5
Jun 25
58.8
Sep 25
57.6
Dec 25
49.1
Jun 26
36.9
Sep 26
Updates
6Nov
BTIG maintains Buy on Akebia Therapeutics, cuts price target to $3
BTIG analyst Julian Harrison maintained a Buy rating on Akebia Therapeutics. Price target lowered from $4 to $3. Rating remains unchanged despite the valuation cut.
7 days ago
5Nov
Akebia Therapeutics Q3 Results: Sales drop 37% to $36.9M, miss estimates
Akebia Therapeutics reported a Q3 loss of $0.05 per share, missing the $0.04 consensus estimate by 25%. Quarterly sales fell to $36.9 million, a 21.39% miss against the $46.941 million analyst estimate. Revenue declined 37.21% year-over-year from $58.766 million in the same period last year.
7 days ago
2Oct
Akebia Therapeutics grants 8,400 stock options to new employee
Granted 8,400 stock options to a newly hired employee on September 30, 2026. Exercise price set at $0.92 per share, equal to the closing price on the grant date. Options vest over four years with 25% on the first anniversary and the rest quarterly. Grant made under Nasdaq Listing Rule 5635(c)(4) as an employment inducement.
1mo ago
2Sep
Akebia Therapeutics grants 8,400 stock options to new employee
Akebia Therapeutics granted 8,400 stock options to a new employee on August 31, 2026. Exercise price set at $0.92 per share, equal to the closing price on the grant date. Options vest over four years, with 25% vesting after one year and the rest quarterly. The grant adheres to Nasdaq Listing Rule 5635(c)(4) for inducement awards.
Akebia Therapeutics beat Q2 EPS and sales estimates but saw revenue fall 21.36% YoY to $49.128M. The company reported EPS of $(0.03) vs $(0.04) estimate.
3mo ago
4Aug
Akebia Therapeutics grants 61,000 stock options to new hires
Akebia Therapeutics issued 61,000 stock options to two new hires on July 31, 2026, at an exercise price of $1.32 per share. The awards vest over four years and comply with Nasdaq Listing Rule 5635(c)(4). The move supports the company’s recruitment efforts in the competitive biopharmaceutical labor market.
